Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 67896049PAH4009 | Other Identifier | Janssen-Cilag S.p.A., Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate the change from baseline to 12 months after study enrollment in the number of the following non-invasive risk criteria: World Health Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with PAH | Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PAH medication | Drug | There will be no specific interventions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in the Number of the Non-Invasive Low-Risk Criteria to 12 Months | Change from baseline in the number of the non-invasive low-risk criteria will be assessed according to the following parameters: world health organization (WHO)/functional class (FC)- I, II, 6-minute walk distance (6MWD) greater than (>) 440 meters (m), and brain natriuretic peptide (BNP) less than (<) 50 nanogram per liter (ng/l) or N-terminal-pro-hormone brain natriuretic Peptide (NT-proBNP) <300 ng/l. | Baseline and 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with Improved, Stable or Worsened Risk profile from Baseline to 12 and 24 Months | Risk profile is assessed as improved, stable or worsened where improved indicates 1 or more non-invasive parameters from intermediate to low risk profile; stable indicates no change in the parameters; and worsened indicates 1 or more non-invasive parameters move from low or intermediate to intermediate or high range risk. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Study population consist of participants with confirmed diagnosis of PAH.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen-Cilag S.p.A., Italy Clinical Trial | Janssen-Cilag S.p.A. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Generale Regionale F. Miulli | Acquaviva delle Fonti | 70021 | Italy | |||
| A.O. Universitaria Ospedali Riuniti di Ancona |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41956554 | Derived | Scelsi L, Badagliacca R, Vicenzi M, Di Poi E, Baldi F, Ameri P, Airo E, Bux F, Lorenzo D, Giuliani L, Perna GP, Bonsante E, D'Agostino C, Raineri C, Agostoni P, Cappuccio A, Greco E, Marini MG, Biancospino M, Uglietti A, De Santis S. Understanding the burden of pulmonary arterial hypertension among patients and caregivers through narrative medicine: data from Italian multicentre observational INSPECTIO study. BMJ Open Respir Res. 2026 Apr 9;13(1):e003377. doi: 10.1136/bmjresp-2025-003377. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline up to 12 and 24 Months |
| Change in Progression in the Number of Participants with Low/High Intermediate Risk | Change in risk profile for the low/high intermediate risk participants according to following cut-off values for low intermediate risk/high intermediate risk, respectively: (6MWD [greater than or equal to [>=] or < 300m], Peak oxygen consumption [VO2] [>= or < 50% predicted], BNP [less than or equal to [<=] or > 175 ng/l], or NT-proBNP [<= or > 850 ng/l], right atrial area [RA] [<= or > 22 centimeter [cm]] and right atrial pressure [RAP] [<= or > 11 millimeter of mercury [mmHg]] or stroke volume index (SVI) (> or <= 38 milliliter per meter square [ml/m2])). The low intermediate risk is defined by a presence of at least three low intermediate parameters and a high intermediate risk is defined by a presence of at least three high intermediate parameters. | Baseline up to 24 Months |
| Change from Baseline in 6MWD | Change from baseline in 6MWD will be reported. | Baseline up to 24 Months |
| Change from Baseline in BNP or NT-proBNP | Change from baseline in BNP or NT-proBNP will be reported. | Baseline up to 24 Months |
| Change from Baseline in Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) 2.0 Risk Score up to 12 and 24 Months | The REVEAL risk calculator determines the risk status and the scores can be defined as: low risk as a score of <= 6, intermediate risk as a score of 7 or 8, and high risk as a score of >= 9 for the survival rates. | Baseline up to 12 and 24 Months |
| Adherence to European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines and 6th World Symposium on Pulmonary Hypertension (WSPH) | Adherence to ESC/ERS guidelines and 6th WSPH will be reported. | Up to 24 Months |
| Change from Baseline in Echocardiographic Parameters | Change in echocardiographic parameters will be reported as assessed by echocardiogram. | Baseline up to 24 Months |
| Change from Baseline in Hemodynamic Parameters | Change in hemodynamic parameters will be reported. | Baseline up to 24 Months |
| Hospitalization Rate due to Worsening of PAH | The hospitalization rate due to PAH worsening will be calculated based on the number of participants with at least one hospitalization. The calculation of the rate will be based on the number of events over the whole follow-up time that is exposure time. | Up to 24 Months |
| Overall Survival (OS) | OS is defined as the duration/time from the start of study treatment to date of death due to any cause. | Up to 24 Months |
| Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured with Emphasis-10 Questionnaire | The emPHasis-10 is a short and easy questionnaire that consists of 10 items which address breathlessness, fatigue, control and confidence. Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. A total emPHasis-10 score is derived using simple aggregation of the 10 items. emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life. | Baseline up to 24 Months |
| Change from Baseline in Participants with Narrative plots | Participants will be invited to fill in two narrative plots; one at the enrollment visit and one at the month 12 visit. | Baseline and 12 Months |
| Change from Baseline in Caregivers with Narrative Plots | Caregivers will be invited to fill in two narrative plots; one at the enrollment visit and one at the month 12 visit. | Baseline and 12 Months |
| Number of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs) | An AE is any untoward medical occurrence in a participant enrolled in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An ADR is defined as a response to a medicinal (investigational or non-investigational) product that is noxious and unintended. | Up to 24 Months |
| Ancona |
| 60126 |
| Italy |
| Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari | Bari | 70124 | Italy |
| Ospedale Di Venere | Bari | 70131 | Italy |
| Ospedale di Bolzano | Bolzano | 39100 | Italy |
| ASST Spedali Civili Brescia | Brescia | 25123 | Italy |
| Azienda Ospedaliera G. Brotzu | Cagliari | 09134 | Italy |
| AO di Catanzaro Pugliese Ciaccio | Catanzaro | 88100 | Italy |
| ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti | Chieti | 66100 | Italy |
| AOU Careggi | Florence | 50134 | Italy |
| Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia | Foggia | 71122 | Italy |
| Ospedale Policlinico San Martino IRCCS | Genova | 16132 | Italy |
| Presidio Ospedaliero di Ivrea | Ivrea | 10015 | Italy |
| Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico | Milan | 20122 | Italy |
| IRCCS Ospedale San Raffaele | Milan | 20132 | Italy |
| Centro Cardiologico Monzino | Milan | 20138 | Italy |
| Ospedale Monaldi | Naples | 80131 | Italy |
| Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara | Novara | 28100 | Italy |
| AOU di Padova | Padova | 35128 | Italy |
| ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione | Palermo | 90127 | Italy |
| Fondazione IRCCS Policlinico San Matteo | Pavia | 27100 | Italy |
| Fondazione Toscana Gabriele Monasterio CNR | Pisa | 56124 | Italy |
| UOC Oncologia Ospedale Provinciale di Macerata | Province of Macerata | 62100 | Italy |
| AOU Policlinico Umberto I | Roma | 00161 | Italy |
| Policinico A Gemelli | Roma | 00168 | Italy |
| IRCCS Policlinico San Donato | San Donato Milanese | 20097 | Italy |
| Presidio SS Annunziata AOU Sassari | Sassari | 07100 | Italy |
| Azienda Ospedaliera Città della Salute e della Scienza di Torino | Torino | 10126 | Italy |
| ASUI Santa Maria della Misericordia di Udine | Udine | 33100 | Italy |
| Ospedale Borgo Roma | Verona | 37134 | Italy |
| ID | Term |
|---|---|
| D000081029 | Pulmonary Arterial Hypertension |
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided